Review Article

Medications That May be Contributing to Your Patient’s Weight Gain

Authors: Jason Powell, PharmD, James Taylor, PharmD

Abstract

Nearly 42% of adults in the United States are considered obese. Although there are a number of contributing factors to obesity, one sometimes overlooked contributor to weight gain is medications. Within many classes of medications that may affect weight, the degree of weight gain varies. Although factors such as efficacy, cost, interactions, and adverse effects play a role in selecting a medication, the effects on weight also should be considered in those who are overweight or obese. This article reviews some of the classes of medications used in the outpatient setting that may affect weight to provide a guide to clinicians.

 

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Centers for Disease Control and Prevention. National diabetes statistics report. https://www.cdc.gov/diabetes/php/data-research/index.html. Published May 15, 2024. Accessed July 9, 2024.
 
2. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med 2017;376:254–266.
 
3. Ward ZJ, Bleich SN, Long MW, et al. Association of body mass index with health care expenditures in the United States by age and sex. PLoS ONE 2021;16:e0247307.
 
4. Centers for Disease Control and Prevention. About obesity. https://www.cdc.gov/obesity/php/about/index.html. Published January 23, 2024. Accessed July 9, 2024.
 
5. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010;71:1259–1272.
 
6. Deshmukh R, Franco K. Managing weight gain as a side effect of antidepressant therapy. Cleve Clin J Med 2003;70:614, 616, 618, passim.
 
7. Dent R, Blackmore A, Peterson J, et al. Changes in body weight and psychotropic drugs: a systematic synthesis of the literature. PLoS ONE 2012;7:e36889.
 
8. Harris B, Young J, Hughes B. Comparative effects of seven antidepressant regimes on appetite, weight and carbohydrate preference. Br J Psychiatry 1986;148:590–592.
 
9. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000;61(Suppl 11):37-41.
 
10. Alam MY, Jacobsen PL, Chen Y, et al. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol 2014;29:36–44.
 
11. Bathla M, Anjum S. A 12-week prospective randomized controlled comparative trial of vilazodone and sertraline in Indian patients with depression. Indian J Pharmacol 2020;52: 10–15.
 
12. Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 1994;14:170–179.
 
13. Gadde KM, Xiong GL. Bupropion for weight reduction. Expert Rev Neurother 2007;7:17–24.
 
14. Anekwe CV, Ahn YJ, Bajaj SS, et al. Pharmacotherapy causing weight gain and metabolic alteration in those with obesity and obesity-related conditions: a review. Ann NY Acad Sci 2024;1533:145–155.
 
15. Domecq JP, Prutsky G, Leppin A, et al. Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab 2015;100: 363–370.
 
16. Ratliff JC, Barber JA, Palmese LB, et al. Association of prescription H1 antihistamine use with obesity: results from the National Health and Nutrition Examination Survey. Obesity (Silver Spring) 2010;18:2398–2400.
 
17. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes—causes, effects and coping strategies. Diabetes Obes Metab 2007;9:799–812.
 
18. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–2443.
 
19. Yerevanian A, Soukas AA. Metformin: mechanisms in human obesity and weight loss. Curr Obes Rep 2019;8:156–164.
 
20. Schnell O, Weng J, Sheu WHH, et al. Acarbose reduces body weight irrespective of glycemic control in patients with diabetes: results of a worldwide, non-interventional, observational study data pool. J Diabetes Complications 2016;30:628–637.
 
21. Sugimoto S, Nakajima H, Kosaka K, et al. Review: miglitol has potential as a therapeutic drug against obesity. Nutr Metab 2015;12:51.
 
22. Ribola FA, Cançado FB, Schoueri JH, et al. Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci 2017;21:199-211.
 
23. Powell J, Taylor J. Use of dulaglutide, semaglutide, and tirzepatide in diabetes and weight management. Clin Ther 2024;46:289-292.
 
24. Wung PK, Anderson T, Fontaine KR, et al.Effects of glucocorticoids on weight change during the treatment of Wegener’s granulomatosis.Arthritis Rheum 2008;59:746–753.
 
25. Verhaegen AA, Van Gaal LF. Drugs That Affect Body Weight, Body Fat Distribution, and Metabolism. South Dartmouth, MA: MDText.com; 2019.
 
26. Wharton S, Raiber L, S4erodio KJ, et al. Medications that cause weight gain and alternatives in Canada: a narrative review. Diabetes Metab Syndr Obes Targets Ther 2018;11:427–438.
 
27. Amatayakul K, Sivasomboon B, Thanangkul O. A study of the mechanism of weight gain in medroxyprogesterone acetate users. Contraception 1980;22:605–622.
 
28. Chandiwana NC, Siedner MJ, Marconi VC, et al. Weight gain after HIV therapy initiation: pathophysiology and implications. J Clin Endocrinol Metab 2024;109:e478– e487.